ArticleSkeletal radiology2026
Detection of metastasis in myxoid liposarcoma: WB-MRI versus CT-CAP.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the incidence and distribution of skeletal and extraskeletal metastases in myxoid liposarcoma (MLS) on staging whole-body MRI (WB-MRI) and CT chest, abdomen, and pelvis (CT-CAP), to inform initial staging protocols. MATERIALS AND
methodsRetrospective review of staging WB-MRI and CT-CAP performed within 60 days in 57 histologically proven MLS cases at a quaternary sarcoma center (October 2018 to August 2022). Findings were classified by consensus as normal, indeterminate, or metastasis (bone, lung, and soft tissue). Primary tumor characteristics were compared between metastatic and nonmetastatic cases.
resultsFifty-seven patients (25 female, 32 male; mean age 46 years) comprised 55 new diagnoses and two recurrences. Median WB-MRI to CT-CAP interval was 0 days (IQR 0 to 8). Among new diagnoses, WB-MRI classified 76% as normal, 13% indeterminate, and 11% metastatic; CT-CAP proportions were 82%, 11%, and 7%. All bone metastases and indeterminate osseous lesions on WB-MRI were occult on CT-CAP or outside the CT field of view (FOV). All extrapulmonary soft tissue lesions within the CT FOV were seen on both. Small pulmonary nodules (< 5 mm) were seen only on CT. All metastases occurred in deep tumors; mean maximum dimension and volume were significantly larger with metastases (19.3 vs. 10.6 cm, p = 0.035; 1566 vs. 399 cm
conclusionOsseous metastases and indeterminate lesions were more frequent on WB-MRI than CT-CAP, whereas extrapulmonary soft tissue metastases were seen on both within the CT FOV. CT chest retained value for small pulmonary nodules. These findings support prospective evaluation of WB-MRI plus CT chest for initial staging in MLS.
Indexed as
Identifiers
42498840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.